This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals

This study has been completed.
World Health Organization
Institute Pedro Kouri, Ministry of Public Health (Cuba)
Centers for Disease Control and Prevention
Information provided by:
Pan American Health Organization Identifier:
First received: November 29, 2005
Last updated: NA
Last verified: January 2004
History: No changes posted
The purpose of this study was to evaluated the effectiveness of inactivated poliovirus vaccine at a vaccine schedule that is commonly used in developing countries. The effectiveness of inactivated poliovaccine given at this schedule is important to national policy makers as they consider vaccination policies after the use of oral polio vaccine is discontinued.

Condition Intervention
Level of Immunity Against Poliovirus Infection Biological: Inactivated Polio Vaccine given at an accelerated schedule

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Randomized Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba

Resource links provided by NLM:

Further study details as provided by Pan American Health Organization:

Primary Outcome Measures:
  • Seroconversion by measuring level of poliovirus antibodies in serum. Also, measure of virus titer in stools to indirectly assess the level of intestinal mucosal immunity

Estimated Enrollment: 300
Study Start Date: August 2001
Estimated Study Completion Date: January 2003
Detailed Description:
After polio eradication, access to live polioviruses will be highly restricted, and oral poliovirus vaccine (OPV) use must be discontinued. OPV-using countries must decide whether to switch to inactivated poliovirus vaccine (IPV) or stop polio vaccination. Because only limited data are available on IPV immunogenicity in tropical developing countries, we conducted a randomized controlled trial of IPV in Cuba. The objectives of this study were to assess the humoral and mucosal immunogenicity conferred by IPV administered at the WHO-EPI schedule (6,10,14 wks of age) vs. placebo. A third arm was added to evaluate the immunogenicity of IPV administered at 2 and 4 months of age. Antibody titers were measured prior to the first dose as well as 1 month after the last dose in each study arm. Target sample size was 100 children in each arm. Mucosal (intestinal immunity) was measured indirectly through assessing poliovirus excretion in each group after a "natural challenge" of trivalent oral polio vaccine (OPV)recieved by study participants through their participation in the annual OPV mass campaigns approximately 1 month after their last dose of vaccine.

Ages Eligible for Study:   6 Weeks to 2 Months   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Infants born 18 – 20 weeks prior to the first round of the 2002 National Immunization Days in cuba (in March 2002).

Born healthy at one of the 4 designated maternity hospitals in Cuba

Exclusion Criteria:

Serious congenital defect/disease at birth

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00260312

Sponsors and Collaborators
Pan American Health Organization
World Health Organization
Institute Pedro Kouri, Ministry of Public Health (Cuba)
Centers for Disease Control and Prevention
Principal Investigator: Miguel Galindo, MD Ministry of Public Health, Cuba
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00260312     History of Changes
Other Study ID Numbers: 3827
Study First Received: November 29, 2005
Last Updated: November 29, 2005

Keywords provided by Pan American Health Organization:

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on July 24, 2017